Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Molecular Biology›Clustered Regularly Interspaced Short Palindromic Repeats
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Clustered Regularly Interspaced Short Palindromic Repeats

Molecular Biology · NLM MeSH · updated 2026-10-29 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 4 min read

Repetitive nucleic acid sequences that are principal components of the archaeal and bacterial crispr-cas systems, which function as adaptive antiviral defense systems.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (740 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

Repetitive nucleic acid sequences that are principal components of the archaeal and bacterial crispr-cas systems, which function as adaptive antiviral defense systems.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Clustered Regularly Interspaced Short Palindromic Repeat; CRISPR Elements; CRISPR Element; Element, CRISPR; Elements, CRISPR; CRISPR Sequences; CRISPR Sequence; Sequence, CRISPR.

Where it fits in the MeSH classification

Broader topics
Inverted Repeat Sequences; Tandem Repeat Sequences
See also
CRISPR-Associated Proteins

Related concepts

  • CRISPR-Cas Systems

Research landscape

PubMed indexes 6,684 records tagged with the MeSH heading “Clustered Regularly Interspaced Short Palindromic Repeats” (counts retrieved 2026-10-29). 3,474 of them (52.0%) were published from 2020 onward, and the busiest period so far is 2020 onward with 3,474 records.

Reviews account for 1,097 records (16.4%) and meta-analyses for 9. Randomized controlled trials number 0 (0.0%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 0 records; 2000-2009: 0 records; 2010-2019: 3,278 records; 2020 onward: 3,474 records0through 199902000-20093,2782010-20193,4742020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19990
2000-20090
2010-20193,278
2020 onward3,474
Share of records by publication typeReviews: 16.4 percent; Meta-analyses: 0.1 percent; Randomized controlled trials: 0.0 percentReviews16.4% (1,097)Meta-analyses0.1% (9)Randomized controlled trials0.0% (0)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 6,684 PubMed records
TypeRecordsShare
Reviews1,09716.4%
Meta-analyses90.1%
Randomized controlled trials00.0%

Method: PubMed query "Clustered Regularly Interspaced Short Palindromic Repeats"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.

Reading the evidence in molecular biology

Molecular biology establishes mechanisms through controlled experiments, often in simplified systems such as purified proteins, cultured cells or model organisms. Such work can show what is possible in a defined system, but whether a pathway matters in a whole organism or in human disease needs further evidence. Check the experimental system, whether findings were reproduced by independent groups, and whether the authors tested the mechanism directly or inferred it from correlation.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors
Replogle JM, Bonnar JL, Pogson AN, Liem CR, Maier NK, Ding Y, et al.
2022Research article
Design not recorded in structured metadata
172cc0
PMID 36576240 · DOI · PMC9829409
Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer
Zhou P, Shi H, Huang H, Sun X, Yuan S, Chapman NM, et al.
2023Research article
Design not recorded in structured metadata
159cc by
PMID 37968405 · DOI · PMC10700132
Simultaneous CRISPR screening and spatial transcriptomics reveal intracellular, intercellular, and functional transcriptional circuits
Binan L, Jiang A, Danquah SA, Valakh V, Simonton B, Bezney J, et al.
2025Research article
Design not recorded in structured metadata
108cc by
PMID 40081369 · DOI · PMC12135205
CRISPR-GPT for agentic automation of gene-editing experiments
Qu Y, Huang K, Yin M, Zhan K, Liu D, Yin D, et al.
2026Research article
Design not recorded in structured metadata
64cc by
PMID 40738974 · DOI · PMC12920143

Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors [1]

Research article Replogle JM, Bonnar JL, Pogson AN, Liem CR, Maier NK, Ding Y, et al. · · 2022 · cited 172 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
CRISPR interference (CRISPRi) enables programmable, reversible, and titratable repression of gene expression (knockdown) in mammalian cells.
Closing excerpt
Our results and publicly available reagents establish best practices for CRISPRi genetic screening.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (168 words)

CRISPR interference (CRISPRi) enables programmable, reversible, and titratable repression of gene expression (knockdown) in mammalian cells. Initial CRISPRi-mediated genetic screens have showcased the potential to address basic questions in cell biology, genetics, and biotechnology, but wider deployment of CRISPRi screening has been constrained by the large size of single guide RNA (sgRNA) libraries and challenges in generating cell models with consistent CRISPRi-mediated knockdown. Here, we present next-generation CRISPRi sgRNA libraries and effector expression constructs that enable strong and consistent knockdown across mammalian cell models. First, we combine empirical sgRNA selection with a dual-sgRNA library design to generate an ultra-compact (1-3 elements per gene), highly active CRISPRi sgRNA library. Next, we compare CRISPRi effectors to show that the recently published Zim3-dCas9 provides an excellent balance between strong on-target knockdown and minimal non-specific effects on cell growth or the transcriptome. Finally, we engineer a suite of cell lines with stable expression of Zim3-dCas9 and robust on-target knockdown. Our results and publicly available reagents establish best practices for CRISPRi genetic screening.

Abstract reproduced from the open-access article under the recorded cc0 licence; © the authors. PMID 36576240 · DOI · PMC9829409

Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer [2]

Research article Zhou P, Shi H, Huang H, Sun X, Yuan S, Chapman NM, et al. · · 2023 · cited 159 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
CD8+ cytotoxic T cells (CTLs) orchestrate antitumour immunity and exhibit inherent heterogeneity1,2, with precursor exhausted T (Tpex) cells but not terminally exhausted T (Tex) cells capable of responding to existing immunotherapies3-7.
Closing excerpt
Collectively, our study reveals that promoting the exit from quiescence of Tpex cells and enriching the proliferative Tex cell state act as key modalities for antitumour effects and provides a systemic framework to integrate cell fate regulomes and reprogrammable functional determinants for cancer immunity.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (237 words)

CD8+ cytotoxic T cells (CTLs) orchestrate antitumour immunity and exhibit inherent heterogeneity1,2, with precursor exhausted T (Tpex) cells but not terminally exhausted T (Tex) cells capable of responding to existing immunotherapies3-7. The gene regulatory network that underlies CTL differentiation and whether Tex cell responses can be functionally reinvigorated are incompletely understood. Here we systematically mapped causal gene regulatory networks using single-cell CRISPR screens in vivo and discovered checkpoints for CTL differentiation. First, the exit from quiescence of Tpex cells initiated successive differentiation into intermediate Tex cells. This process is differentially regulated by IKAROS and ETS1, the deficiencies of which dampened and increased mTORC1-associated metabolic activities, respectively. IKAROS-deficient cells accumulated as a metabolically quiescent Tpex cell population with limited differentiation potential following immune checkpoint blockade (ICB). Conversely, targeting ETS1 improved antitumour immunity and ICB efficacy by boosting differentiation of Tpex to intermediate Tex cells and metabolic rewiring. Mechanistically, TCF-1 and BATF are the targets for IKAROS and ETS1, respectively. Second, the RBPJ-IRF1 axis promoted differentiation of intermediate Tex to terminal Tex cells. Accordingly, targeting RBPJ enhanced functional and epigenetic reprogramming of Tex cells towards the proliferative state and improved therapeutic effects and ICB efficacy. Collectively, our study reveals that promoting the exit from quiescence of Tpex cells and enriching the proliferative Tex cell state act as key modalities for antitumour effects and provides a systemic framework to integrate cell fate regulomes and reprogrammable functional determinants for cancer immunity.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 37968405 · DOI · PMC10700132

Simultaneous CRISPR screening and spatial transcriptomics reveal intracellular, intercellular, and functional transcriptional circuits [3]

Research article Binan L, Jiang A, Danquah SA, Valakh V, Simonton B, Bezney J, et al. · · 2025 · cited 108 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Pooled optical screens have enabled the study of cellular interactions, morphology, or dynamics at massive scale, but they have not yet leveraged the power of highly plexed single-cell resolved transcriptomic readouts to inform molecular pathways.
Closing excerpt
Perturb-FISH is thus a general method for studying the genetic and molecular associations of spatial and functional biology at single-cell resolution.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (163 words)

Pooled optical screens have enabled the study of cellular interactions, morphology, or dynamics at massive scale, but they have not yet leveraged the power of highly plexed single-cell resolved transcriptomic readouts to inform molecular pathways. Here, we present a combination of imaging spatial transcriptomics with parallel optical detection of in situ amplified guide RNAs (Perturb-FISH). Perturb-FISH recovers intracellular effects that are consistent with single-cell RNA-sequencing-based readouts of perturbation effects (Perturb-seq) in a screen of lipopolysaccharide response in cultured monocytes, and it uncovers intercellular and density-dependent regulation of the innate immune response. Similarly, in three-dimensional xenograft models, Perturb-FISH identifies tumor-immune interactions altered by genetic knockout. When paired with a functional readout in a separate screen of autism spectrum disorder risk genes in human-induced pluripotent stem cell (hIPSC) astrocytes, Perturb-FISH shows common calcium activity phenotypes and their associated genetic interactions and dysregulated molecular pathways. Perturb-FISH is thus a general method for studying the genetic and molecular associations of spatial and functional biology at single-cell resolution.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 40081369 · DOI · PMC12135205

CRISPR-GPT for agentic automation of gene-editing experiments [4]

Research article Qu Y, Huang K, Yin M, Zhan K, Liu D, Yin D, et al. · · 2026 · cited 64 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Performing effective gene-editing experiments requires a deep understanding of both the CRISPR technology and the biological system involved.
Closing excerpt
CRISPR-GPT enables fully AI-guided gene-editing experiment design and analysis across different modalities, validating its effectiveness as an AI co-pilot in genome engineering.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (172 words)

Performing effective gene-editing experiments requires a deep understanding of both the CRISPR technology and the biological system involved. Meanwhile, despite their versatility and promise, large language models (LLMs) often lack domain-specific knowledge and struggle to accurately solve biological design problems. We present CRISPR-GPT, an LLM agent system to automate and enhance CRISPR-based gene-editing design and data analysis. CRISPR-GPT leverages the reasoning capabilities of LLMs for complex task decomposition, decision-making and interactive human-artificial intelligence (AI) collaboration. This system incorporates domain expertise, retrieval techniques, external tools and a specialized LLM fine tuned with open-forum discussions among scientists. CRISPR-GPT assists users in selecting CRISPR systems, experiment planning, designing guide RNAs, choosing delivery methods, drafting protocols, designing assays and analysing data. We showcase the potential of CRISPR-GPT by knocking out four genes with CRISPR-Cas12a in a human lung adenocarcinoma cell line and epigenetically activating two genes using CRISPR-dCas9 in a human melanoma cell line. CRISPR-GPT enables fully AI-guided gene-editing experiment design and analysis across different modalities, validating its effectiveness as an AI co-pilot in genome engineering.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 40738974 · DOI · PMC12920143

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article CRISPR-Cas9 Structures and Mechanisms [5]
    Jiang F, Doudna JA · Annu Rev Biophys · 2017 · cited 1,386 times (Europe PMC)
  • Research article The next generation of CRISPR-Cas technologies and applications [6]
    Pickar-Oliver A, Gersbach CA · Nat Rev Mol Cell Biol · 2019 · cited 1,064 times (Europe PMC)
  • Research article Delivering CRISPR: a review of the challenges and approaches [7]
    Lino CA, Harper JC, Carney JP, Timlin JA · Drug Deliv · 2018 · cited 811 times (Europe PMC)
  • Research article CRISPR/Cas Genome Editing and Precision Plant Breeding in Agriculture [8]
    Chen K, Wang Y, Zhang R, Zhang H, Gao C · Annu Rev Plant Biol · 2019 · cited 807 times (Europe PMC)
  • Research article CRISPR technology: A decade of genome editing is only the beginning [9]
    Wang JY, Doudna JA · Science · 2023 · cited 781 times (Europe PMC)
  • Research article Cornerstones of CRISPR-Cas in drug discovery and therapy [10]
    Fellmann C, Gowen BG, Lin PC, Doudna JA, Corn JE · Nat Rev Drug Discov · 2017 · cited 345 times (Europe PMC)

References

  1. Replogle JM, Bonnar JL, Pogson AN, Liem CR, Maier NK, Ding Y, et al.. Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors. . 2022. PMID 36576240 · DOI · PMC9829409
  2. Zhou P, Shi H, Huang H, Sun X, Yuan S, Chapman NM, et al.. Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer. . 2023. PMID 37968405 · DOI · PMC10700132
  3. Binan L, Jiang A, Danquah SA, Valakh V, Simonton B, Bezney J, et al.. Simultaneous CRISPR screening and spatial transcriptomics reveal intracellular, intercellular, and functional transcriptional circuits. . 2025. PMID 40081369 · DOI · PMC12135205
  4. Qu Y, Huang K, Yin M, Zhan K, Liu D, Yin D, et al.. CRISPR-GPT for agentic automation of gene-editing experiments. . 2026. PMID 40738974 · DOI · PMC12920143
  5. Jiang F, Doudna JA. CRISPR-Cas9 Structures and Mechanisms. Annu Rev Biophys. 2017. PMID 28375731 · DOI
  6. Pickar-Oliver A, Gersbach CA. The next generation of CRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol. 2019. PMID 31147612 · DOI · PMC7079207
  7. Lino CA, Harper JC, Carney JP, Timlin JA. Delivering CRISPR: a review of the challenges and approaches. Drug Deliv. 2018. PMID 29801422 · DOI · PMC6058482
  8. Chen K, Wang Y, Zhang R, Zhang H, Gao C. CRISPR/Cas Genome Editing and Precision Plant Breeding in Agriculture. Annu Rev Plant Biol. 2019. PMID 30835493 · DOI
  9. Wang JY, Doudna JA. CRISPR technology: A decade of genome editing is only the beginning. Science. 2023. PMID 36656942 · DOI
  10. Fellmann C, Gowen BG, Lin PC, Doudna JA, Corn JE. Cornerstones of CRISPR-Cas in drug discovery and therapy. Nat Rev Drug Discov. 2017. PMID 28008168 · DOI · PMC5459481

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-29.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • Response ElementsMolecular Biology
  • CpG IslandsMolecular Biology
  • TATA BoxMolecular Biology
  • Consensus SequenceMolecular Biology
  • Conserved SequenceMolecular Biology
  • Amino Acid SequenceMolecular Biology

All 100 articles in Molecular Biology →

At a glance

6,684
PubMed records on this heading
52%
published since 2020
1,097
review articles
0
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-29; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • Response ElementsMolecular Biology
  • CpG IslandsMolecular Biology
  • TATA BoxMolecular Biology
  • Consensus SequenceMolecular Biology
  • Conserved SequenceMolecular Biology

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support